Success from the Niche: Xeris Biopharma Holdings with Strong Revenue Increase Thanks to Specialized Therapies
Reading Time: 2 minutes
Xeris Biopharma Holdings is a biopharmaceutical company specializing in the development and marketing of therapies for patients with chronic endocrine and neurological disorders. Its main products include Gvoke and Recorlev. Both drugs specifically address conditions with high medical need and offer practical solutions for both acute and long-term therapies. Record Revenue Driven by Strong Demand for Recorlev and Gvoke Xeris Biopharma has raised the bar in the fourth quarter of 2024: With a revenue jump to 60 million US dollars, the company not...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
